Mumbai, May 29 -- The facility was inspected between 22 April and 27 April 2026. The certification confirms that the plant complies with EU GMP standards and can cater to regulated European markets.

Aditi Panandikar, managing director of Indoco Remedies, said the certification reflects the company's commitment to supplying high-quality products to patients across the globe.

Meanwhile, ICICI Prudential Mutual Fund acquired 13,58,002 shares, or a 1.47% stake, in Indoco Remedies through bulk deals on 27 May 2026. Exchange data showed that the fund bought 6,83,544 shares on the NSE and 6,74,458 shares on the BSE at Rs 198 per share. The total deal value stood at around Rs 26.88 crore.

Indoco Remedies is a fully integrated pharmaceutical co...